The Impact of Azacitidine and Venetoclax Versus Intensive Chemotherapy Induction on Outcomes after Allogeneic Stem-Cell Transplantation for Newly Diagnosed Acute Myeloid Leukemia.

Key Points

• Azacitidine and venetoclax show promising outcomes compared to intensive chemotherapy in acute myeloid leukemia patients.
• Overall survival rates were significantly improved with azacitidine and venetoclax versus conventional chemotherapy.
• Assessment of treatment outcomes involved a cohort of patients newly diagnosed with acute myeloid leukemia.
• These findings highlight the need for evolving therapeutic approaches to enhance survival in this high-risk population.